SCHEMBL458455

SCHEMBL458455

O=C(O)c1cc(Cl)ccc1NOCCCc1cccc(-c2ccoc2)c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 7/20 0.62
CNR1 P21554 1/20 0.41
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
PPARD Q03181 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
MPO P05164 1/20 0.36
AKR1C4 P17516 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CDK2 P24941 1/20 0.35
POLB P06746 1/20 0.35
G6PD P11413 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420159 0.81 SERPINE1 (0.71) SERPINE1CNR1PPARDNR1H4HCAR2
SCHEMBL418577 0.79 SERPINE1 (0.73) SERPINE1CNR1AKR1C4AKR1C3AKR1C2
SCHEMBL458450 0.78 SERPINE1 (0.56) SERPINE1CNR1FABP3FABP4MPO
SCHEMBL460371 0.77 SERPINE1 (0.61) SERPINE1CNR1FABP3FABP4MPO
SCHEMBL1015517 0.77 SERPINE1 (1.00) SERPINE1CNR1FABP3FABP4AKR1C4
SCHEMBL1014985 0.75 SERPINE1 (1.00) SERPINE1CNR1HCAR2KDM4EPOLB
SCHEMBL420979 0.73 SERPINE1 (1.00) SERPINE1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL419000 0.73 SERPINE1 (0.60) SERPINE1CNR1PPARDNR1H4HCAR2
SCHEMBL1012706 0.73 SERPINE1 (0.80) SERPINE1CNR1FABP3FABP4MPO
SCHEMBL29838682 0.73 SERPINE1 (1.00) SERPINE1POLBG6PD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885CNR1 3208/4885FABP3 722/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885CNR1 3208/4885FABP3 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.